The the benefits of Tirzepatida they will more than the number shown for scale. The drug was initially developed for the treatment of type 2 diabetes, and, later on, began to be studied in a comprehensive way in the control of chronic weight, showing the effects on appetite and glucose, waist circumference, and various markers in the metabolic.
In Brazil, the Tirzepatida is present in the Mounjaro. The Fda has approved a drug to improve glycemic control in type 2 diabetes, and, by the year 2025, it has expanded the indication for the control of chronic weight of adults who meet the criteria set forth, always in conjunction with a diet with a calorie reduction and increased physical activity.
It is important, however, to separate that which is already approved indication of that which appears as a result of favorable in the study. The reduction of the albuminúria, the improvement of the obstructive sleep apnea, and changes in the factors for cardiovascular disease, for example, there are scientific findings that are relevant, but they should not be turned on automatically at the promise of a treat for everyone.
In this article, you are going to understand exactly what the main the benefits of Tirzepatidawhat has been shown in clinical trials, and what are the limitations to watch out for this discussion.
- Important: this content is purely informative and does not replace evaluation by a doctor. The display of the Tirzepatida depends on the diagnosis, clinical records, the risks and needs of each person.
How to Tirzepatida does it work?
The Tirzepatida is an agonist of the long duration of action of the receptors for GIP and GLP-1.
These two hormonal systems involved in the control of glucose metabolism. The Tirzepatida increase in the secretion of insulin in a manner dependent on the glucose, and reduces glucagon, under certain conditions, it enhances the sensitivity to insulin, slows down the gastric emptying time, and acted upon by mechanisms that are related to the hungry, and over and over again.
In practice, a lot of people are feeling less hungry, and most satisfied with smaller portions.
This combination of effects may help to explain why the medicine, it may give rise to improvement in glycemic and a significant reduction in the weight of the body.
1. Weight loss is clinically significant
Between the benefits of Tirzepatida the most well-known is the reduction in the proportion of people with obesity or overweight, and that meet the criteria for treatment.
In this study SURMOUNT-1, which is included 2.539 in adults with obesity or overweight and without diabetes, the reduction in the average weight after 72 weeks was approximately as follows:
- To 15.0% with a 5-mg);
- The 19.5% and 10%;
- 20.9% in the 15 mg;
- 3.1% for placebo.
They are medium-sized groups, and are not a prediction of the individual.
Some of the people who have lost more weight, and less of the participants discontinued the treatment for a variety of reasons.
The clinical significance of weight loss it is not only in the appearance. To reduce excess weight, it can improve mobility, blood pressure, blood sugar levels, quality of sleep, and the different factors that are related to the risk of cardiometabólico.
2. Leaving the country is also a part of the treatment
The one point that is often overlooked is that obesity is a chronic disease.
Don't you just see how much weight has been lost in the first few months. It is also important to know if the treatment will help you maintain your results.
Your own statement be transferred to the control of chronic weight-includes loss and weight maintenance.
This will change the way you see the point. The Tirzepatida should not be treated simply as a means to quickly reach a certain number on the scale, and then be left without a plan.
Studies on the removal show that we recover a part of the weight, it's possible, when treatment is stopped, thus reinforcing the importance of the maintenance strategy.
3. Less hunger and greater satiety
Other the benefits of Tirzepatida this is the an influence on appetite and food intake.
The Fda describes the Tirzepatida, reduces food intake, increases satiety and controls the appetite.
This can cause some people to understand:
- less hungry between meals.
- satisfied with smaller portions;
- the reduction in the desire to repeat;
- the lower the frequency of the constant thoughts about food.
These changes can make it easy to create a shortage of energy needed for weight loss.
However, it felt a little hungry doesn't mean that your body no longer do you need protein, vitamins, minerals, dietary fiber and fluids.
A reduction in excess in the diet can make it more difficult for the preservation of lean muscle mass and increase the risk of inadequate nutrition.
4. The improvement of glucose control
The Tirzepatida was originally approved for type 2 diabetes, and glycemic control continues to be one of their more well-established.
The drug increases the release of insulin in a manner dependent upon that of glucose, and improves insulin sensitivity.
In people with type 2 diabetes, the study will SURPASS showed significant reductions in hemoglobin glicada.
In 2026, the Fda also expanded the indication of the Mounjaro for type 2 diabetes in pediatric patients 10 years of age, while the indication is transferred to the control of chronic weight-it remains focused on the criteria of an approved adult.
For those who have diabetes, this needs to be monitored because of the combination of insulin, or sulfonilureias may increase the risk of hypoglycaemia requiring the evaluation of the doses used by the professional in charge.
5. The improvement of insulin resistance
Insulin resistance happens when the tissues, such as muscle, liver and fat tissue, accounting for less and less properly to the action of this hormone.
It appears frequently in people with obesity, pre-diabetes, and type 2 diabetes.
The Tirzepatida improves, sensitivity to insulin, and is a part of the change is related to the weight loss.
It can help the body to be able to monitor your glucose with the lowest demand on the beta cells of the pancreas.
To this effect, it does not mean that all of a person with a “high insulin” to have it automatically indication for the use of the product.
The resistance to the insulin that needs to be interpreted within the context of the age in full.
6. The lower the progression to diabetes in people with obesity and pre-diabetes
One of the findings of the long-term, the more interesting it came to pass on the extent of the SURMOUNT-1.
Among participants with obesity and pre-diabetes, diabetes, accompanied for 176 weeks ago, type 2 diabetes, is diagnosed in approximately 1.3% of the participants treated with Tirzepatida, and 13.3% of those who received a placebo.
This result is a significant reduction in the progression to diabetes in the study population.
It is one of the the benefits of Tirzepatida the most relevant features of the metabolic point of view, but it needs to be put into context correctly.
The participants had obesity, pre-diabetes, and you were in a clinical trial. In the result, it does not mean that any person who has a blood sugar (glucose) to discreetly high, due to start Tirzepatida to “not to give a diabetic”.
7. The reduction in waist circumference
A measuring tape, you can display the changes in the balance alone does not say.
In the sub-body of the SURMOUNT-1, the participants in the treated showed an average reduction is important in the waist circumference after 72 weeks.
This reduction is included with the reduction of body fat, and abdominal fatness.
Waist-it is important because a higher concentration of fat in the abdominal region is associated with insulin resistance and increased risk of cardiometabólico.
It is not measured directly, and the fat that sits around your organs, but it is a very simple tool to keep track of changes in the body during treatment.
8. The reduction of body fat, and visceral fat
In the same sub-we used DXA, to analyze the composition of your body.
After 72 weeks, the group Tirzepatida showed an average reduction of approximately 33.9 percent of the mass in a fatwhile the overall weight has fallen 21.3 per cent.
About three-quarters of the weight loss corresponding to the mass of the fat, and about one-fourth of the lean body mass.
It is important to note that muscle mass does not mean a purely muscle. This includes water, organs, and other tissues, with no fat at all.
The data also showed a significant reduction of visceral adiposity.
This is one of the the benefits of Tirzepatida it helps to explain why we keep track of only kilograms, it can hide a part of the metabolic changes produced during weight loss.
9. Blood pressure can be lower
Studies are performed on people with obesity have observed a reduction in the values of arterial blood pressure during the treatment process.
At the SURMOUNT-1, in both the systolic and the diastolic showed an improvement in comparison to placebo.
A sub that used ambulatory monitoring, for 24 hours and also found a reduction in systolic blood pressure throughout the day and night.
A portion of this effect is likely to be linked to one's own weight-loss.
It doesn't make Tirzepatida, in particular medicine for high blood pressure.
Anyone who uses losartana, amlodipine were reported, or other antihypertensive should not stop the treatment because it started to lose weight. In some cases, a large reduction of weight, it may lead the doctor to adjust the dosage.
10. Serum triglycerides, and other markers, lipids can be improved
The weight loss and increase metabolism also be able to modify the lipid profile.
Clinical trials and meta-analyses found a reduction in serum triglycerides, total cholesterol, and LDL, and increase HDL in the different populations.
The triglycerides are among the markers that have shown the changes are broadly consistent.
Even so, this doesn't make the Tirzepatida in the replacement of statins or other medications that are used specifically to reduce the risk of cardiovascular disease.
A person can lose weight a lot and continue on with the LDL is high, especially when there is a strong genetic component.
11. The benefits on body composition and go beyond the appearance of
Losing weight is not just “getting smaller”.
One of the advantages of the watch body is to know the weight is coming off.
In the study, the majority of the reduction occurred in the bulk of the fat, but there was also a loss of lean body mass.
This highlights the importance of the use of the treatment, along with strategies to promote the preservation of the muscles.
The protein properly, strength training, physical activity, and caloric intake are not too low, these are aspects that are important for the great loss of weight.
For this reason, the the benefits of Tirzepatida they should be evaluated together with the quality of weight loss, it is not just the speed.
12. Obstructive sleep apnea can be improved in people with obesity
The SURMOUNT-OPTIMIZATION studied in adults with obesity and obstructive sleep apnea is moderate to severe.
After 52 weeks, the participants, and are treated with Tirzepatida showed a significant reduction in the contents of the long-hipopneia, and body weight compared with placebo.
This result shows how obesity may influence the disease are directly related to the excess weight.
However, the improvement of the skin-it does not mean that a person is able to leave the GENERATOR on its own.
The need of the device needs to be re-evaluated by means of follow-up, and, when indicated, to a new sleep study.
13. There are some signs that are favorable for the kidneys
The analysis of the studies that will SURPASS and to SURMOUNT found a reduction in the albuminúria and fall more slowly in the glomerular filtration rate in certain populations.
The SURPASS-4, for example, in people with type 2 diabetes and high cardiovascular risk subjects showed a reduction of more slowly in the s, with Tirzepatida of insulin glargina.
These results are very promising indeed.
But it is important to turn to a finding of secondary education, in a statement that it does not exist.
The Tirzepatida should not be presented as if it were, automatically, to a specific drug for chronic kidney disease.
In addition, vomiting, and diarrhea, intense, it can cause dehydration and lead to acute kidney injury, especially in people who are most vulnerable.
14. What do we know about heart health?
The improvement in weight, blood pressure, blood sugar, and triglycerides, create your own profile cardiometabólico better.
In addition to this, the SURPASS-CVOT brought about an important piece of information on cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease is established.
In the present study, cardiovascular death, heart attack, or STROKE) occurred in approximately 12.2% of the participants treated with Tirzepatida and 13.1% of those treated with dulaglutida.
The Tirzepatida has reached the criterion of statistical non-inferiority.but he has not shown superiority of the statistic for the outcome of the primary.
Therefore, it is correct to say that there is evidence that cardiovascular-relevant and supportive of the safety of the treatment in this population.
It is not proper to act as a result of a promise that the Tirzepatida prevent a heart attack in a person.
15. The quality of life and exercise capacity also matters
Results of the metabolic shall not be assessed by the tests.
For some, it's a significant loss of excess weight can make it easier to activities that were previously difficult to walk long distances, climb stairs, exercise or perform the tasks of your everyday life.
It can also occur in the improvement of the conditions that are related to your weight, such as sleep apnea, high pressure, and mobility limitations.
These changes can have a real impact on their quality of life.
However, individual response varies, and the purpose of the processing shall be construed in accordance with the clinical status and functional for each and every person.
The benefit does not mean the absence of risk
For a discussion of the responsible person on the benefits of Tirzepatida you also need to talk to you about safety and security.
The most frequent adverse events are gastrointestinal, including nausea, diarrhea, constipation, vomiting, indigestion, and abdominal pain.
Also, there are important caveats related to pancreatitis, gallbladder disease, dehydration, acute kidney injury, and in other situations.
In addition, the drug has contraindications, and precautions that need to be assessed prior to the treatment.
For this reason, the use Tirzepatida just because the other person first is a good way to decide if the drug is indicated.
How long does it take for you to realise the benefits?
There is no time limit.
Some of the changes in appetite and food intake may be seen in the first few weeks.
The weight, waist size, blood sugar and other markers of change over time.
In the major clinical trials of obesity, the results of which are analysed over the course of many months, not just days.
This is important because there is a tendency in the social networks, and to assess the success, or failure, the loss was obtained in about a week or two.
The response to treatment should be regarded as a trend.
The most weight loss that mean more to you?
Not ever.
A person can lose a lot of weight too quickly, because you are taking into your body of calories and nutrients are not enough.
If this is the case, it can lead to weakness, excessive loss of lean body mass and nutritional deficiencies.
The goal should not be to achieve the greatest possible reduction in the minimum time.
In one treatment, well-conducted, aimed at improving weight and health, while at the same time.
The the benefits of Tirzepatida they need to be evaluated by the whole composition of the body, tests, peer pressure, physical activity, nutrition, and well-being.
Who can benefit from the treatment.
The display depends on the purpose.
In Brazil, the Tirzepatida have an indication for type 2 diabetes, and for the control of chronic, of the weight of the criteria are approved by the Fda.
For weight management in adults, indicating that includes obesity, or being overweight is associated with the at least one co-morbidity related to their weight, according to regulatory criteria.
This is not to say that all of the people within the range of the BMI not necessarily need to use the medicine.
Medical history, previous treatments, the risks, preferences, and associated conditions need to be in the final.
Frequently asked questions
What are the main benefits of the Tirzepatida?
The effects of the most well-established and include loss and weight maintenance in people who meet the criteria, the reduction of appetite, increased satiety, and improves glycemic control in type 2 diabetes. The studies also showed favorable changes in the waist, fat in the body, peer pressure, triglycerides, and other markers in the metabolic.
Tirzepatida is only for weight loss?
No. It was initially developed and approved to improve glycemic control in type 2 diabetes. For the control of chronic weight is another measure passed in the criteria.
It helps those who have pre-diabetes?
In the follow-up of 176 weeks in the SURMOUNT-1, for people with obesity and pre-diabetes in treated subjects showed a much lower rate of progression to type 2 diabetes than those who received a placebo.
Tirzepatida it improves cholesterol?
Studies have shown an improvement of the different components of the lipid profile, especially triglycerides. This doesn't mean that you replace the drugs that are specific for the reduction of LDL cholesterol when they are first listed.
It will reduce visceral fat?
Studies of body composition and found a significant reduction in body fat and visceral adiposity during the treatment period.
Tirzepatida it's good for the heart.
It can improve various different risk factors cardiometabólico. The SURPASS-CVOT, it was no less than the dulaglutida for cardiovascular death, heart attack or STROKE in people with type 2 diabetes and heart disease is established. It is not to be construed as a guarantee of cardiovascular prevention to the public.
They all get the same benefits?
No. In response, weight loss, and adverse effects, and changes in the metabolism varies greatly between individuals.
Conclusion
The the benefits of Tirzepatida the more solids that are related to glycemic control and chronic treatment of overweight in the population for which the medicine is designed and approved.
At the SURMOUNT-1, and the average loss is arrived at approximately 20.9% in the 72-week at a dose of 15 mg). In addition to the weight, the study showed a reduction in waist circumference, fat mass and visceral adiposity.
In people with type 2 diabetes, there is evidence of a robust improvement in the blood sugar (glucose).
Among participants with obesity and pre-diabetes, diabetes, accompanied by 176 weeks in the progression to diabetes was much lower, with Tirzepatida than with placebo.
There are also favourable outcomes on blood pressure, lipid profile, obstructive sleep apnea and markers in the kidney.
However, these findings should not be turned on, a list of promises.
For some, they correspond to the indications that have been approved. The others are the benefits observed in the specific population (s) within the study, and are still under investigation.
At the same time, there are side effects and risks that need to be in the final.
For this reason, the best way to evaluate the the benefits of Tirzepatida it is to ask not only, “as she makes you lose weight?”, but the treatment can be improved in order to secure the table, metabolic, functional, and clinical terms with that person.
References
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. SURMOUNT-1.
Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England Journal of Medicine.
Look M, et al. Body composition changes during weight reduction with tirzepatide to the SURMOUNT of-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism.
Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England Journal of Medicine.
Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England Journal of Medicine. SURPASS-CVOT.
Heerspink HJL, et al. The Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes-in-the-SURPASS-4 trial.
Content is up-to-date in August, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida the cause of indigestion? To understand the onset of discomfort after eating
Tirzepatida gives you diarrhea? Find out why it happens and what to do
